Dean Li, Merck Research Laboratories president
Back again: Merck willing to dole out more than $9B for Kelun’s ADCs
While all has gone quiet on the M&A rumor front for Seagen, one of the pioneers in antibody-drug conjugates, Merck has been racking up deal …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
